Described herein are synthetic progestogens, such as 6β,7β15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.

A method of reducing silver(I) salts to silver nanoparticles employing a carbohydrate reductant in the presence of an inorganic base, a surfactant and optionally a polymer. The method is performed in an aqueous solution at a temperature up to 60° C. and for a duration of up to 40 minutes.

A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compostions related to plasma dried by the methods of the present invention.

Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm.sup.3 and about 0.15 g/cm.sup.3, and/or a specific surface area (SSA) of at least 18 m.sup.2/g, 20 m.sup.2/g, 25 m.sup.2/g, 30 m.sup.2/g, 32 m.sup.2/g, 34 m.sup.2/g, or 35 m.sup.2/g. Methods for making and using such compositions are also provided.

A powder injection of a donepezil semi palmoxiric acid salt, a composition containing the same and a preparation method therefor. The powder injection contains donepezil semi palmoxiric acid salt crystals, and the average grain size of the crystals ranges from 0.5 μm to 100 μm.

The present invention is directed to an improved method for preparing bisantrene, specifically bisantrene dihydrochloride, for intravenous administration, as well as to preparations of bisantrene dihydrochloride for intravenous administration. The present invention is also directed to methods for treatment of malignancies treatable by administration of bisantrene, which can include administration of additional anti-neoplastic agents, wherein the bisantrene is prepared by a method according to the present invention.

The present invention relates to a method for preparing a granule or a pill containing a plant, medicinal herb or traditional oriental medicine decoction extract, having the steps of: (a) injecting a powdered plant, medicinal herb or traditional oriental medicine decoction extract into a fluidized-bed device and spraying purified water or a solution of the same type of extract as the extract powder at the extract powder while fluidizing the same, thereby generating microgranules of the extract powder; and (b) injecting the microgranules generated at step (a) as seeds into the fluidized-bed device and spraying a solution of the extract while fluidizing the same, thereby growing the microgranules to a predetermined size of granule or pill. According to the present invention, it is possible to prepare a granule or a pill containing an extract in a high concentration.

Provided herein are pharmaceutical compositions for treating human lung diseases comprising a stabilized DNase I polypeptide containing a non-standard amino acid, a functional fragment thereof, or a variant thereof that maintains enzymatic activity even under harsh conditions, such as reducing environments. The present disclosure also relates to methods of using the composition for the treatment of human of lung diseases or for the disruption of biofilms.

The present disclosure relates to granules comprising an L-amino acid and a method for preparing the same. The method may comprise: (a) preparing a fermentation liquid of L-amino acid; (b) removing moisture from the fermentation liquid of L-amino acid such that the solid content of the fermentation liquid of L-amino acid is in a range of 20% to 90%; (c) forming granulated particles with a moisture content of 0% to 40% by mixing the concentrated fermentation liquid of L-amino acid with a seed; (d) drying the granulated particles formed in Step (c); (e) sieving the granulated particles dried in Step (d); and (f) pulverizing or circulating the particles left in step (e) to be recycled as the seed in step (c).

Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.